DiaGenic ASA announced that chief executive officer, Erik Christensen, MD PhD, has notified the board of directors that he would like to resign from his position with effect from April 17, 2012. Erik Christensen will continue to provide consultative support to the company on partner interactions, licensing and other business activities. Chairman of the board of directors of the company, Henrik Lund MD PhD, has been constituted as the chief executive officer from and including April 17, 2012 until a new chief executive officer is employed. Henrik Lund will from the same date leave the board of directors. Deputy chairman of the board of directors, Ingrid Wiik, will act as chairman of the board of directors until the annual general meeting of the company to be held on June 5, 2012. Erik Christensen has been the Chief Executive Officer of DiaGenic since 2007, and has managed the company during development of blood based diagnostic tests for Alzheimer's disease and breast cancer.